Preclinical study conducted by Dentaid Research Center and Irsicaixa investigators. 2 sub-studies: Lentivirus with expressed Spike protein → to determine the ability of CPC to inhibit the entrance of the virus in human cells. SARS-CoV-2 isolated from COVID-19+ patient → to analyze the ability of CPC to reduce the infectivity of SARS-CoV-2. Mouthwash analyzed included 0.07% CPC, 0.05% CPC+0.12% CHX, CPC diluted in water and their placebos (same formulas without CPC. Mouthwashes containing 0.05% and 0.07% CPC were able to reduce 1000 times (3 orders of magnitude) the infectivity of SARS-CoV-2 in this in vitro study.